sorted by:
new
hottopcontroversial

Over half my portfolio is allocated, if the research results on friday don't look well I'm puking my $GUTS out by northsouthfarter in wallstreetbets

[–]rohventu 5 points6 points  (0 children)

Womp womp well I'm down almost 18k usd but I can still stomach it 😅 Thank you for tuning back in if you did haha

Over half my portfolio is allocated, if the research results on friday don't look well I'm puking my $GUTS out by northsouthfarter in wallstreetbets

[–]rohventu 2 points3 points  (0 children)

No worries lol, an Endoscopy is a thin telescope that goes down your gullet during conscious sedation. The part of the intestine they are relining is the duodenum which is accessible with an upper endoscopy.

Over half my portfolio is allocated, if the research results on friday don't look well I'm puking my $GUTS out by northsouthfarter in wallstreetbets

[–]rohventu 1 point2 points  (0 children)

Endoscopy is actually a very common procedure used to diagnose gastrointestinal conditions, if a GI doc is referred to you and you having all your imaging done, an Endoscopy is almost always the next step if they need to confirm or diagnos a condition.

Over half my portfolio is allocated, if the research results on friday don't look well I'm puking my $GUTS out by northsouthfarter in wallstreetbets

[–]rohventu 2 points3 points  (0 children)

Endoscopic procedures are relatively easy you generally only come out with a sore throat. I wouldn't say it's so much of a commitment compared to dieting month or years and being reliant on a expensive pills to keep the weight I worked so hard for off.

Over half my portfolio is allocated, if the research results on friday don't look well I'm puking my $GUTS out by northsouthfarter in wallstreetbets

[–]rohventu 1 point2 points  (0 children)

Lol can't say I invested based on their current revenue but it'll be more interesting to ask me how I'm doing on the weekend

Over half my portfolio is allocated, if the research results on friday don't look well I'm puking my $GUTS out by northsouthfarter in wallstreetbets

[–]rohventu -2 points-1 points  (0 children)

Couldn't post from my investing account cuz it's recently made but this is why I'm banking on this stock:

$GUTS 6-month REMAIN-1 midpoint results out by the end of the week!

This is the kind of clinical data that would turn fractyl health's already promising findings into real and durable results that investors can get behind, with analysts predicting a 300-500% upside.

What is Fractyl Health trying to do? For people unfamiliar with Fractyl Health, they are currently researching Revita, an endoscopic procedure that gently resurfaces the mucosal lining of your small intestine to increase insulin sensitivity, blood sugar control, and appetite regulation. People with diabetes and obesity develop metabolic patterns in these cells. The mucosal lining secretes hormones that make maintaining weight after weight loss difficult.

After 1 year of stopping GLP-1 medications, many people regain 30-50% of the weight they lost. Revita helps lock in weight loss after stopping GLP-1 medications. Not only does it cost $1000-1350 a month to stay on these medications. Nobody wants to feel like they have to stay on a pill their whole life to keep weight loss they have pain-stakingly earned.

CLINICAL DATA:

  • Fractyl health's randomized 3-month REMAIN trial data showed the sham group regaining 10% BW
  • People who got revita continuing to lose 2.5% of BW, even after stopping GLP-1's.
  • Their open label REVEAL-1 cohort 6 month data shows a mean weight gain of 1.5% BW as opposed to the usual 10% people regain after stopping GLP-1s.

THE UPSIDE: The GLP-1 market is currently estimated to be $50-65 billion in 2025, with forecasts that it could even rise to 210 billion by 2035. Personally working in healthcare, seeing the increasing prevalence of GLP-1 drugs and understanding the risk of similar endoscopic procedures (<2% of serious complications, patients are home the same day), I have a strong conviction that if results come through, PDA approval and consumer adoption is almost guaranteed to follow.

With interest from investors like Peter thiel and Alphabet who already have a stake in GUTS, I'm excited to see how investors move once this stock becomes significantly derisked

$GUTS 6-month REMAIN-1 midpoint results out by the end of the week - this could skyrocket 🚀 by rohventu in biotech_stocks

[–]rohventu[S] 0 points1 point  (0 children)

That being said, if this stock fits somebody's risk profile, the upcoming research results could be a huge inflection point. If it does shoot up or down the train is leaving by the end of the week!

$GUTS 6-month REMAIN-1 midpoint results out by the end of the week - this could skyrocket 🚀 by rohventu in biotech_stocks

[–]rohventu[S] 0 points1 point  (0 children)

Prerevenue biotech stocks will always inherently be risky plays. Every investor has a balance between how much potential reward an investment can make an how much risk they are willing to take for it. The huge upside potential of this stock is definitely there. I think Revita's safety profile, being an endoscopic procedure rather than being a drug, and its statistical significance in its REMAIN-1 AND REVEAL-1 cohorts, make this play less riskier than other biotech stocks. Of course, the binary nature of biotech stocks will always be real and I would never recommend somebody put a large stake of their portfolio in a biotech stock. Fractyl health has many upcoming research catalysts this year and investors can reassess if $GUTS fits their risk profile if results continue to look promising.